- Question from SmithS: What was the most important update for metastatic patients (particularly HER2 patients)?
- Answers - Generosa Grana, M.D., F.A.C.P I would say that the most exciting thing was the realization that there is improved understanding of the pathways involved in breast cancer, including the HER2 pathway, and that various strategies are being used to approach those pathways jointly. It will no longer be an issue with having only trastuzumab. There was interesting data combining trastuzumab and lapatinib (brand name: Tykerb) , as well as incorporation of other agents that may play a role in this pathway. So the future for HER2 positive disease looks very promising.
The Ask-the-Expert Online Conference called Updates From the 2008 ASCO Annual Meeting featured Generosa Grana, M.D., F.A.C.P. and Carol Kaplan, M.D. answering your questions about the latest research advances on screening, treatment, side effects, and more.
Editor's Note: This conference took place in June 2008.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.